Nuventra’s Associate Director of Clinical Pharmacology, Lauren R. L. Lohmer, Ph.D., will be presenting during the upcoming PBSS San Francisco Symposium titled, “Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks.”
Dr. Lohmer’s presentation will focus on new opportunities for concentration-QT (C-QT) and C-QT in non-ideal scenarios. In an effort to reduce risk to patients, regulatory agencies now require rigorous analysis of QT intervals in clinical trials as a measure of drug safety. This seminar will discuss the various ways to evaluate cardiac safety using a variety of methods – as early as preclinical and throughout your clinical trials.
Dr. Lohmer will be presenting during the symposium alongside presenters from ERT Clinical Trial Technology Solutions, Spaulding Clinical, Merck, Terns Pharmaceuticals, and Genentech. This symposium will be offered as a free online webcast and will take place March 23, 2021 – March 24, 2021 | 8:30am – 12:30pm PT.
Date & Time: March 23 – 24, 2021 | 8:30am – 12:30pm PT
Location: Online via Zoom
Registration deadline: March 22 (registration will close before if seating cap is reached)
For more information on the workshop and to register for the event:
- Borje Darpo, Chief Scientific Officer, iCardiac
- Jay Mason, Chief Medical Officer, Spaulding Clinical
- Bela Patel, Executive Director, Head of Pharmacometrics, Merck
- Anne Bonneville, Sr. Director Toxicology, Terns Pharmaceuticals
- Yehong Wang, Clinical Pharmacologist, Genentech